AB002. S1-1. Recent adventure in cholangiocarcinoma—focus on molecular profiling

Yun Yen

Center for Cancer and Translational Research, Taipei Medical University, Taipei, Taiwan

Correspondence to: Yun Yen. Center for Cancer and Translational Research, Taipei Medical University, Taipei, Taiwan.
Email: yyen@tmu.edu.tw.

Abstract: Cholangiocarcinoma (CCA) is a malignant disease of the gallbladder and has gradually increased in incidence over the past 20 years. CCA is the second most common primary liver cancer in the world. CCA is classified into two categories—Intrahepatic and extrahepatic. Because CCA is known to be resistant to multiple drugs, this condition carries poor prognosis, once it is diagnosed. There are several known risk factors for CCA. They include liver fluke infection, primary sclerosing cholangitis, choledochal cysts, viral infections, hepatolithiasis and carcinogen exposure. In this report, we will review current therapeutic options and examine the effect of therapeutic options in combination. The molecular and genomic finding in CCA will be discussed as well.

Keywords: Cholangiocarcinoma; molecular profiling; therapeutic options